David S. Boyer
Impact in
- Ophthalmology top 0.01%
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Ocular Diseases and Behçet’s Syndrome
- Radiology, Nuclear Medicine and Imaging top 0.02%
- Retinal Imaging and Analysis
- Retinal and Macular Surgery
- Retinopathy of Prematurity Studies
Papers in
- Ophthalmology 148
- Retinal Diseases and Treatments 136
- Retinal and Optic Conditions 70
- Glaucoma and retinal disorders 37
- Ocular Diseases and Behçet’s Syndrome 11
- Intraocular Surgery and Lenses 4
-
- Retinal Imaging and Analysis 85
- Retinal and Macular Surgery 17
- Co-authors
- Jeffrey S. HeierDavid M. BrownPeter K. KaiserPhilip J. RosenfeldCarol ChungRobert Y. KimRobert B. BhisitkulSrinivas R. Sadda
- Journals
- Ophthalmology (29 papers)Investigative Ophthalmology & Visual Science (26 papers)Retina (17 papers)American Journal of Ophthalmology (14 papers)Ophthalmology Retina (9 papers)
- Partner nations
- United StatesGermanySwitzerland
In The Last Decade
David S. Boyer
177 papers receiving 16.0k citations
Hit Papers
Peers
Comparison fields: 5 of 137
- Ophthalmology 14.9k
- Radiology, Nuclear Medicine and Imaging 11.2k
- Molecular Biology 3.1k
- Clinical Biochemistry 241
- Neurology 276
Countries citing papers authored by David S. Boyer
This map shows the geographic impact of David S. Boyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Boyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Boyer more than expected).
Fields of papers citing papers by David S. Boyer
This network shows the impact of papers produced by David S. Boyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Boyer. The network helps show where David S. Boyer may publish in the future.
Co-authors
The 25 scholars most cited alongside David S. Boyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2023 | 32 | |
| 3 | Intravitreal Injection of Allogeneic Human Retinal Progenitor Cells (hRPC) for Treatment of Retinitis Pigmentosa: A Prospective Randomized Controlled Phase 2b Trial | 2021 | 3 |
| 4 | Oral Administration of the Complement Factor D Inhibitor Danicopan (ALXN2040) in Preclinical Studies Demonstrates High and Sustained Drug Concentrations in Posterior Ocular Tissues for the Potential Treatment of Geographic Atrophy | 2021 | 6 |
| 5 | 2020 | 55 | |
| 6 | 2020 | 2 | |
| 7 | Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-Related Macular Degeneration | 2020 | 3 |
| 8 | Ocular Pharmacokinetics and Safety of Suprachoroidal A01017, Small Molecule Complement Inhibitor, Injectable Suspension in Rabbits | 2020 | 8 |
| 9 | Treatment of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy with Intravitreal Aflibercept Injection: 52-Week Results from the Phase 3 PANORAMA Study | 2019 | 1 |
| 10 | Intravitreal Nesvacumab+Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Trial | 2018 | 3 |
| 11 | A combined phase 2a/b study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) | 2016 | 4 |
| 12 | Reactive Oxygen Species Levels in Human Retinal Pigment Epithelium Cells In vitro to anti-VEGF Agents: Ranibizumab, Bevacizumab, Aflibercept and Ziv-aflibercept | 2015 | 2 |
| 13 | Efficacy and Safety of Intravitreal Aflibercept Injection (IAI) for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO): 24-Week Results of the VIBRANT Study | 2014 | 2 |
| 14 | A Phase 2b Study of Fovista™, a Platelet Derived Growth Factor (PDGF) inhibitor in combination with a Vascular Endothelial Growth Factor (VEGF) inhibitor for Neovascular Age-Related Macular Degeneration (AMD) | 2013 | 11 |
| 15 | Integrin Peptide Therapy: A New Class of Treatment for Vascular Eye Diseases - The First Human Experience in DME | 2012 | 2 |
| 16 | 2011 | 3 | |
| 17 | Combined Inhibition of Platelet Derived (PDGF) and Vascular Endothelial (VEGF) Growth Factors for the Treatment of Neovascular Age-Related Macular Degeneration (NV-AMD) - Results of a Phase 1 Study | 2009 | 18 |
| 18 | A Phase I Open-Label Study of Single and Repeated Doses of Intravitreal JSM6427, a Small Molecule Integrin 5β1 Antagonist, in Neovascular Age-Related Macular Degeneration (AMD) | 2008 | 3 |
| 19 | 1998 | 20 | |
| 20 | 1998 | 2 |
About David S. Boyer
David S. Boyer is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging, Immunology and Allergy, Immunology and Molecular Biology, having authored 185 papers that have together received 16.8k indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (136 papers), Retinal Imaging and Analysis (85 papers), Retinal and Optic Conditions (70 papers), Glaucoma and retinal disorders (37 papers), Retinal Development and Disorders (23 papers), Retinal and Macular Surgery (17 papers), Ocular Diseases and Behçet’s Syndrome (11 papers) and Intraocular Surgery and Lenses (4 papers). The work is most often cited by research in Ophthalmology (14.9k citations), Radiology, Nuclear Medicine and Imaging (11.2k citations), Molecular Biology (3.1k citations), Clinical Biochemistry (241 citations) and Neurology (276 citations). David S. Boyer has collaborated with scholars based in United States, Germany and Switzerland. Frequent co-authors include Jeffrey S. Heier, David M. Brown, Peter K. Kaiser, Philip J. Rosenfeld, Carol Chung, Robert Y. Kim, David M. Brown, Robert B. Bhisitkul, Srinivas R. Sadda and Quan Dong Nguyen. Their work appears in journals such as Ophthalmology, Investigative Ophthalmology & Visual Science, Retina, American Journal of Ophthalmology and Ophthalmology Retina.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.